The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MDS 2021 | MDS: managing HMA failure
Hypomethylating agents (HMA), such as azacitidine and decitabine are standard of care for myelodysplastic syndromes (MDS). However, there remain few options for patients who fail HMAs, which indeed a great many do. Valeria Santini, MD, University of Florence, Florence, Italy, discusses rescue strategies for this patient population. This interview took place during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes.
